AlzeCure presents novel Alzstatin data at the 11th Symposium on Pharmaceutical Profiling meeting
Home HEALTHCARE AlzeCure presents novel Alzstatin data at the 11th Symposium on Pharmaceutical Profiling meeting

AlzeCure presents novel Alzstatin data at the 11th Symposium on Pharmaceutical Profiling meeting

Published by Redaktionen

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract with new promising preclinical Alzstatin data has been accepted for a poster presentation at the 11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development on January 27, 2022, at the Humanities Theatre, English Park Campus, Uppsala.

The poster, titled Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, will be presented by Dr. Maria Backlund at the 11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development, hosted by Uppsala University’s Department of Pharmacy. Other authors include Sanja Juric, Dr. Johan Sandin, CSO at AlzeCure and Dr. Gunnar Nordvall, Head of Chemistry at AlzeCure.

The aim of the work was to explore the effect of AlzeCure’s compound AC-0027875 on Aβ42 reduction, i.e reducing the production of toxic amyloid beta, in animals as well as to assess its pharmacokinetic properties. AC- 0027875 is a novel potent small molecule γ-secretase modulator and part of AlzeCure’s research platform Alzstatin. γ-Secretase modulators, so called GSMs, represent a promising class of Aβ42-lowering anti- amyloidogenic compounds for treatment of Alzheimer’s disease. GSMs exhibit several key features that make them suitable as a disease-modifying or preventive treatment of presymptomatic Alzheimer’s disease.

“It is established that Aβ plays a key pathogenic role in Alzheimer’s and begins to accumulate in the brain years before clear symptoms develop. Although these are still preclinical data, it’s encouring to see the results indicating that GSMs, such as our AC-0027875, reduces toxic Aβ42 production making them highly promising as therapy for the treatment of Alzheimer’s disease,” said Johan Sandin, CSO at AlzeCure Pharma.

AlzeCure presents novel Alzstatin data at the 11th Symposium on Pharmaceutical Profiling meeting

Martin Jönsson, CEO of AlzeCure Pharma AB

“With Alzstatin we at Alzecure want to offer a preventive and disease modifying treatment against Alzheimer’s in the form of a oral therapy, which is non-invasive for patients, and the progress we are making is encouraging,” said Martin Jönsson, CEO at AlzeCure Pharma.

The abstract and the poster will be available on AlzeCure’s website after the presentation (https://www. alzecurepharma.se/en/publications).

Related Posts

We use cookies to improve user experience, and analyze website traffic. For these reasons, we may share your site usage data with our analytics partners. By clicking “Accept Cookies,” you consent to store on your device all the technologies described in our Cookie Policy. Accept Read More